-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Lm7uy8oaqPe2H7zzCBi+sJZDXc7+6KqBuGW55RQFbOPamlZ6GkwuKQQuHPI4YLxe OgdokpZ53mMYH9VoYBC0dQ== 0000898432-08-000096.txt : 20080208 0000898432-08-000096.hdr.sgml : 20080208 20080208164816 ACCESSION NUMBER: 0000898432-08-000096 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080208 DATE AS OF CHANGE: 20080208 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS, L.P. GROUP MEMBERS: INVESTMENT 10, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TAPESTRY PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0000891504 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 841187753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49101 FILM NUMBER: 08589802 BUSINESS ADDRESS: STREET 1: 4840 PEARL EAST CIRCLE STREET 2: SUITE 300W CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 303-516-8500 MAIL ADDRESS: STREET 1: 4840 PEARL EAST CIRCLE STREET 2: SUITE 300W CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: NAPRO BIOTHERAPEUTICS INC DATE OF NAME CHANGE: 19940421 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 SC 13G/A 1 sc13ga.htm





SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549



SCHEDULE 13G

(Rule 13d-102)


INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)


(Amendment No. 2)*



Tapestry Pharmaceuticals, Inc.

(Name of Issuer)

 

 

Common Stock

(Title of Class of Securities)


876031204

(CUSIP Number)


 

December 31, 2007

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

 

o Rule 13d-1(b)
ý Rule 13d-1(c)
o Rule 13d-1(d)



*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 2 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
Biotechnology Value Fund, L.P.
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 Delaware

 

 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 367,322 (1)

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 367,322 (1)

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 367,322 (1)

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 2.2 % (1)(2)

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 PN

 

 

 






 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 3 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
Biotechnology Value Fund II, L.P.
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 256,161 (1)

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 256,161 (1)

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 256,161 (1)

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 1.5% (1) (2)

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 PN

 

 

 






 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 4 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
BVF Investments, L.L.C.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

  967,314 (1)

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 967,314 (1)


 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 967,314 (1)

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 5.7% (1) (2)

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 OO

 

 

 






 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 5 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
Investment 10, L.L.C.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Illinois

 

 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 108,406 (1)

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 108,406 (1)

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 108,406 (1)

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 0.6% (1) (2)

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 OO

 

 

 







 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 6 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
BVF Partners L.P.
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 


 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,699,203 (1)

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

1,699,203 (1)


 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 1,699,203 (1)

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 9.9% (1) (2)

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 PN

 

 

 





 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 7 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
BVF Inc.
 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 


 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,699,203 (1)

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 1,699,203 (1)

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 1,699,203 (1)

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 9.9% (1) (2)

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 IA, CO

 

 

 



The following footnotes relate to pages 2 through 7:

(1) With respect to the securities reported in this Amendment No. 2 to Schedule 13G, the Reporting Persons purchased 1,500,000 shares of Common Stock (as defined in Item 2(d)) and received 1,500,000 Warrants (as defined in Item 2(d)) from the issuer in a private placement transaction on April 5, 2006. The Warrants are exercisable for an equivalent number of shares of Common Stock at an exercise price of $2.40 per share (subject to adjustment), at any time until expiration on April 5, 2011. The Warrants provide that in no event shall the Warrants be exercisable if the shares of Common Stock to be issued upon any exercise of the Warrants, after taking into consideration the shares of Common Stock already owned by the Reporting Persons, would result in the beneficial ownership by the Reporting Persons of greater than 9.999% (the "Limitation") of the total number of issued and outstanding shares of Common Stock of the issuer. The Reporting Persons ha ve the right to waive the Limitation upon 60 days written notice to the issuer. Accordingly, the Reporting Persons are deemed to be the owners of 1,699,203 shares of Common Stock, or 9.90% of the shares of Common Stock deemed issued and outstanding as of December 31, 2007. This number assumes the beneficial ownership of the Warrants subject to the Limitation.

(2) The percentage calculations are based on 16,629,861 shares of Common Stock outstanding and only 378,803 shares of Common Stock issuable upon any exercise of the Warrants held by the Reporting Persons as a result of the Limitation.



 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 8 of 10 Pages

 

 

 

 

 

 


ITEM 1(a).      NAME OF ISSUER:

                         Tapestry Pharmaceuticals, Inc. (“Tapestry”)

ITEM 1(b).      ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

4840 Pearl East Circle

Suite 300W

Boulder, CO 80301

ITEM 2(a).      NAME OF PERSON FILING:

                         This Amendment No. 2 to Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

 

(i)

 

 Biotechnology Value Fund, L.P. ("BVF")

 

(ii)

 

 Biotechnology Value Fund II, L.P. ("BVF2")

 

(iii)

 

 BVF Investments, L.L.C. ("Investments")

 

(iv)

 

 Investment 10, L.L.C. ("ILL10")

 

(v)

 

 BVF Partners L.P. ("Partners")

 

(vi)

 

 BVF Inc. ("BVF Inc.")

ITEM 2(b).      ADDRESS OF PRINCIPAL BUSINESS OFFICE:

                         The principal business office of the Reporting Persons comprising the group filing this Amendment No. 2 to Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.

ITEM 2(c).      CITIZENSHIP:

 

 

 BVF:

 a Delaware limited partnership

 

 

 BVF2:

 a Delaware limited partnership

 

 

 Investments:

 a Delaware limited liability company

 

 

 ILL10:

 an Illinois limited liability company

 

 

 Partners:

 a Delaware limited partnership

 

 

 BVF Inc.:

 a Delaware corporation

ITEM 2(d).      TITLE OF CLASS OF SECURITIES:

                This Amendment No. 2 to Schedule 13G is being filed with respect to the common stock, par value $0.0075 per share (the "Common Stock"), of Tapestry. The Reporting Persons' percentage ownership of the Common Stock is based on (i) 16,629,861 shares of Common Stock being outstanding and (ii) the beneficial ownership by the Reporting Persons of 378,803 warrants (the "Warrants") to purchase an equivalent number of shares of the Common Stock. See the discussion in footnote (1) for a discussion of the Warrants held by the Reporting Persons, including the Limitation (as defined in footnote (1)).


         As of December 31, 2007, (i) BVF beneficially owned 367,322 shares of Common Stock, of which 81,887 shares are attributable to Warrants; (ii) BVF2 beneficially owned 256,161 shares of Common Stock, of which 57,106 shares are attributable to Warrants; (iii) Investments beneficially owned 967,314 shares of Common Stock, of which 215,643 shares are attributable to Warrants; and (iv) ILL10 beneficially owned 108,406 shares of Common Stock, of which 24,167 shares are attributable to Warrants. Beneficial ownership by Partners and BVF Inc. includes 1,699,203 shares of Common Stock, of which 378,803 shares are attributable to Warrants.


ITEM 2(e).      CUSIP Number:

                        876031204






 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 9 of 10 Pages

 

 

 

 

 

 


ITEM 3.

IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS:    One of the following

Not applicable as this Amendment No. 2 to Schedule 13G is filed pursuant to Rule 13d-1(c).

ITEM 4.

OWNERSHIP:

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Amendment No. 2 to Schedule 13G is hereby incorporated by reference.

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. 

ITEM 6.

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in shares of the Common Stock beneficially owned by Investments and to vote and exercise dispositive power over those shares of the Common Stock. Partners and BVF Inc. share voting and dispositive power over shares of the Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as an investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of the Common Stock owned by such parties.

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Not applicable.

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:

Not applicable.

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP:

Not applicable.






 

 

 

 

 

CUSIP No. 876031204

 

13G

 

Page 10 of 10 Pages

 

 

 

 

 

 


ITEM 10.

CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:

 

February 1, 2008



 


 


BIOTECHNOLOGY VALUE FUND, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert
President


 


 


BIOTECHNOLOGY VALUE FUND II, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert
President


 


 


BVF INVESTMENTS, L.L.C.


 


 


By:


 


BVF Partners L.P., its manager


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert
 President



 


 


INVESTMENT 10, L.L.C.


 


 


By:


 


BVF Partners L.P., its attorney-in-fact


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert
President


 


 


BVF PARTNERS L.P.


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert
President


 


 



BVF INC.


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert
President





 -----END PRIVACY-ENHANCED MESSAGE-----